

Freedom of Information Request: Our Reference CTMUHB_430_22

You asked:

1. For the 4 months from May to August 2022, how many patients received the following anti-VEGF treatments for any eye condition:

Aflibercept	2076
Bevacizumab	14
Brolucizumab	0
Dexamethasone	50
Faricimab	0
Ranibizumab – Lucentis	8
Ranibizumab – Ongavia	0

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatment listed below, excluding patients who previously had any anti-VEGF therapy

Aflibercept
Bevacizumab
Brolucizumab
Dexamethasone
Faricimab
Ranibizumab – Lucentis
Ranibizumab - Ongavia

This level of information is not captured on our Medicines Management system. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl through all the Ophthalmology patients treated within this timeframe and would significantly exceed the 18 hours' time and £450 cost limit set out within Section 12 of the Freedom of Information Act.